Equillium Inc (EQ)
0.713
-0.07
(-9.23%)
USD |
NASDAQ |
Jun 14, 16:00
0.7012
-0.01
(-1.65%)
After-Hours: 20:00
Equillium Research and Development Expense (Quarterly): 9.743M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 9.743M |
| December 31, 2023 | 9.184M |
| September 30, 2023 | 8.974M |
| June 30, 2023 | 9.61M |
| March 31, 2023 | 9.272M |
| December 31, 2022 | 8.525M |
| September 30, 2022 | 8.771M |
| June 30, 2022 | 9.488M |
| March 31, 2022 | 10.76M |
| December 31, 2021 | 7.549M |
| September 30, 2021 | 6.965M |
| June 30, 2021 | 5.985M |
| March 31, 2021 | 5.88M |
| December 31, 2020 | 6.567M |
| Date | Value |
|---|---|
| September 30, 2020 | 4.218M |
| June 30, 2020 | 3.893M |
| March 31, 2020 | 4.706M |
| December 31, 2019 | 5.449M |
| September 30, 2019 | 4.182M |
| June 30, 2019 | 4.25M |
| March 31, 2019 | 3.759M |
| December 31, 2018 | 2.518M |
| September 30, 2018 | 1.222M |
| June 30, 2018 | 0.54M |
| March 31, 2018 | 0.663M |
| December 31, 2017 | 0.4824M |
| September 30, 2017 | 0.0499M |
| June 30, 2017 | 0.8014M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.893M
Minimum
Jun 2020
10.76M
Maximum
Mar 2022
7.199M
Average
7.257M
Median
Research and Development Expense (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |
| iBio Inc | 0.904M |
| Theriva Biologics Inc | 3.459M |
| Oragenics Inc | 0.6634M |